title: 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
abstract: Docetaxel has an established role in the treatment of metastatic castrate-resistant prostate cancer. A number of recent treatments have been shown to improve the survival outcomes for this group of patients and many with improved toxicity profiles, bringing the role of docetaxel into question. We discuss the results and implications of the CHAARTED study that demonstrated a significant improvement in overall survival with docetaxel in metastatic hormone-sensitive prostate cancer.
authors.affiliation: Department of Medical Oncology, Guy's Hospital, Great Maze Pond, London, UK.
authors.forename: Mark
authors.initials: M
authors.lastname: Voskoboynik
authors.forename: John
authors.initials: J
authors.lastname: Staffurth
authors.forename: Zafar
authors.initials: Z
authors.lastname: Malik
authors.forename: Christopher
authors.initials: C
authors.lastname: Sweeney
authors.forename: Simon
authors.initials: S
authors.lastname: Chowdhury
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods / Q000401:mortality; D000077143:Docetaxel; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate / Q000639:trends; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel
keywords: CHAARTED; Sweeney; docetaxel; hormone sensitive; metastatic prostate cancer